Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: (WFRF:(Delgado Graciela E.)) srt2:(2017) > Oxidized LDL, stati...

Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis

Wagner, Sandra (author): Univ Paris 11, UVSQ, Univ Paris Saclay, Inserm U1018, Villejuif, France.

Apetrii, Mugurel (author): Hop Ambroise Pare, AP HP, Serv Nephrol, Boulogne, France.;Univ Med & Pharm Gr T Popa, Dept Nephrol, Iasi, Romania.

Massy, Ziad A. (author): Univ Paris 11, UVSQ, Univ Paris Saclay, Inserm U1018, Villejuif, France.;Hop Ambroise Pare, AP HP, Serv Nephrol, Boulogne, France.

Kleber, Marcus E. (author): Friedrich Schiller Univ, Inst Nutr, Jena, Germany.;Heidelberg Univ, Med Fac Mannheim, Dept Med Nephrol Hypertensiol Endocrinol Diabetol, Mannheim, Germany.

Delgado, Graciela E. (author): Heidelberg Univ, Med Fac Mannheim, Dept Med Nephrol Hypertensiol Endocrinol Diabetol, Mannheim, Germany.

Scharnagel, Hubert (author): Med Univ Graz, Inst Clin Med, Graz, Austria.;Med Univ Graz, Chem Lab Diagnost, Graz, Austria.

Maerz, Winfried (author): Heidelberg Univ, Med Fac Mannheim, Dept Med Nephrol Hypertensiol Endocrinol Diabetol, Mannheim, Germany.;Med Univ Graz, Inst Clin Med, Graz, Austria.;Med Univ Graz, Chem Lab Diagnost, Graz, Austria.;Synlab Holding Deutschland GmbH, Synlab Acad, Mannheim, Germany. CHU Nancy, Ctr Invest Clin Plurithemat 14 33, INSERM, Nancy, France.

Metzger, Marie (author): Univ Paris 11, UVSQ, Univ Paris Saclay, Inserm U1018, Villejuif, France.

Rossignol, Patrick (author): ALTIR, Vandoeuvre Les Nancy, France.

Jardine, Alan (author): British Heart Fdn Glasgow, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.

Holdaas, Hallvard (author): Natl Hosp Norway, Oslo, Norway.

Fellström, Bengt (author): Uppsala universitet,Njurmedicin

Schmieder, Roland (author): Univ Hosp Erlangen Numberg, Erlangen, Germany.

Stengel, Benedicte (author): Univ Paris 11, UVSQ, Univ Paris Saclay, Inserm U1018, Villejuif, France.

Zannad, Faiez (author)

show less...

Univ Paris 11, UVSQ, Univ Paris Saclay, Inserm U1018, Villejuif, France Hop Ambroise Pare, AP HP, Serv Nephrol, Boulogne, France.;Univ Med & Pharm Gr T Popa, Dept Nephrol, Iasi, Romania. (creator_code:org_t)

2017-01-25
2017
English.
In: Free radical research. - : Taylor & Francis. - 1071-5762 .- 1029-2470. ; 51:1, s. 14-23

Related links:: https://urn.kb.se/re...; show more...; https://doi.org/10.1...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Statin treatment reduces the risk of cardiovascular mortality in the general population, but it has little or no benefit in hemodialyzed (HD) patients. This may reflect different underlying pathophysiology of cardiovascular disease (CVD) in patients treated with HD, maybe involving the oxidative stress. Our aim was to assess the association of oxidized low-density lipoprotein (oxLDL), determined by Mercodia oxLDL enzyme-linked immunosorbent assay (ELISA) kit, with major adverse cardiac events (MACE) and all-cause mortality in HD patients based on the AURORA trial (rosuvastatin vs placebo), and patients not on HD from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. We also assessed whether its decrease due to statin use improves these outcomes using Cox proportional hazard models. Baseline oxLDL level was 34.2 +/- 13.8 U/L in AURORA and did not differ between treatment groups, and 74.6 +/- 28.1 U/L in LURIC. Lower baseline oxLDL levels were associated with higher hazard ratios (HRs) for outcomes, but not anymore after adjusting for apolipoprotein B level in AURORA and was not related to mortality in LURIC. OxLDL levels decreased by 30.9% between baseline and 3 months in the statin-treated group and increased by 10.5% between 3 and 12 months. Nevertheless, oxLDL reduction was not significantly associated with adjusted HRs for MACE and for all-cause mortality. These results showed no association between oxLDL and MACE after adjustment on apolipoprotein B, which may relate to the properties of the method used for oxLDL. Our results also showed no benefit for oxLDL reduction by rosuvastatin on outcomes. Future clinical trials are needed to define the relative CVD risks and benefits of other modalities of oxidative stress modification in this population.

Subject headings

NATURVETENSKAP -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Keyword

Oxidized LDL
hemodialyzed patients
statin
mortality
cardiovascular risks

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

Free radical research (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Wagner, Sandra; Apetrii, Mugurel; Massy, Ziad A.; Kleber, Marcus E ...; Delgado, Graciel ...; Scharnagel, Hube ...; show more...; Maerz, Winfried; Metzger, Marie; Rossignol, Patri ...; Jardine, Alan; Holdaas, Hallvar ...; Fellström, Bengt; Schmieder, Rolan ...; Stengel, Benedic ...; Zannad, Faiez; show less...

About the subject

NATURAL SCIENCES: NATURAL SCIENCES; and Biological Scien ...; and Biochemistry and ...

Articles in the publication: Free radical res ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se